BMS and Pharmasset partnered to evaluate BMS-790052 in combination with PSI-7977 to treat chronic HCV

Pharmasset Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Bristol-Myers Squibb Co.

U.S. / Large-Cap Biopharma (>=$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced